Nature's Bioceuticals debuts Breathing Relief Formula

Nature's Bioceuticals debuts Breathing Relief Formula

Nature's Bioceuticals renames formula to conform with DSHEA and comply with dietary supplement regulations and avoiding NDI filing.

Nature's Bioceuticals, a wholly owned subsidiary of Mistral Ventures Inc. ( announced that it is finalizing arrangements to commence production of its Breathing Relief Formula. This is the formula that the company has previously referred to as its COPD formula, which will now be marketed as a dietary supplement under the Dietary Supplement Health and Education Act of 1994 (DSHEA), thus requiring a name change.

Robert deZanger, CEO of Nature's Bioceuticals stated, "I am extremely satisfied that our new strategy allows us to market this product as a supplement immediately, instead of waiting many years and spending hundreds of millions of dollars seeking FDA approval as a drug. We have begun placing orders for the natural ingredients, bottles, etc. and expect to have product inventory ready for sale within 30 to 60 days. We are also finalizing our new product labeling and packaging, which we feel provides the proper image for our company and products. We anticipate sales in excess of $10,000,000.00 the first year and then expanding and exponentially thereafter."

About Nature's Bioceuticals:

Nature's Bioceuticals develops and acquires the rights to natural medicine formulas that are geared towards treating specific medical conditions. These medicines are all natural and derived from botanicals and mineral bases. Nature's Bioceuticals strives to provide high quality natural medicines that are as effective, if not more effective, than synthetic drugs and more importantly do not have the negative side effects usually associated with many of today's prescribed drugs.

Nature's line of natural medicines will be either sold as prescription drugs, if applied for by the company and approved by the FDA, or sold as dietary supplements under the Dietary Supplement Health and Education Act of 1994, commonly referred to as "DSHEA"

In addition to historical information, this release contains forward-looking statements. Mistral Ventures, Inc. and/or Nature's Bioceuticals may, from time to time, make written or oral forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements encompass Mistral Ventures, Inc. and/or Nature's Bioceuticals beliefs, expectations, hopes, or intentions regarding future events. Words such as "expects," "intends," "believes," "anticipates," "should," "likely," and similar expressions identify forward-looking statements. All forward-looking statements included in this release are made as of the date hereof and are based on information available to the Company as of such date. Neither Mistral Ventures, Inc. nor Nature's Bioceuticals assume any obligation to update any forward-looking statement. Actual results will vary, and may vary materially, from those anticipated, estimated, projected or expected for a number of reasons, including, among others: further reviews of the Company's financial statements by the Company and its Audit Committee; modification of the Company's accounting practices; foreign business risks; industry cyclicality; fluctuations in customer demand and order pattern; changes in pricing and general economic conditions; as well as other risks that may be delineated from time to time or filed with the SEC.

Media Contact: 
Financial Insights
Phone Number: 888 656 3509
E-mail: [email protected]


Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.